Volume 23, supplement 1, Février 2016

Éditorial

Treatment of hepatitis C with NS5A inhibitors (p.4-7)
Jean-Michel Pawlotsky
Free Access

Mini-Revues

Anti-NS5A: mechanism of action, pharmacology and virological characteristics (p.8-19)
Sylvie Larrat
Free Access

NS5A inhibitors with sofosbuvir: place in the management of genotype 3 patients (p.20-6)
Christophe Hézode
Free Access

Sofosbuvir and NS5A inhibitors in HIV/HCV co-infected patients (p.27-32)
Stanislas Pol
Free Access

Treatment of HCV with Direct Acting Antivirals (DAAs) in patients before and after liver transplantation (p.33-8)
Stéphanie Faure, Georges-Philippe Pageaux
Free Access

Management of hepatitis C: Challenges and perspectives (p.39-46)
Victor de Lédinghen
Free Access